Skip to main content

Risk of Hypertension Up With Use of Oral Estrogen-Only Hormone Therapy

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, June 8, 2023 -- For postmenopausal women using estrogen-only hormone therapy (HT), oral estrogen-only HT use is associated with increased risk of hypertension, according to a study published online June 5 in Hypertension.

Cindy Z. Kalenga, from the Cumming School of Medicine at the University of Calgary in Canada, and colleagues conducted a population-based cohort study involving women aged ≥45 years who filled at least two consecutive prescriptions for estrogen-only HT to examine the association between route of administration with hypertension risk. Data were included for 112,240 women who used an estrogen-only form of HT.

The researchers found that compared with transdermal and vaginal estrogens, oral estrogen was associated with a higher risk of hypertension (hazard ratios, 1.14 and 1.19, respectively). Compared with estradiol, conjugated equine estrogen was associated with increased risk of hypertension (hazard ratio, 1.08); no increased risk was seen for estrone. Positive associations were seen for duration of estrogen exposure and cumulative dose of estrogen with risk of hypertension.

"It's really important to have greater knowledge on safe and effective hormonal treatments for women during menopause," a coauthor said in a statement. "At the end of the day, it's an individualized decision about what is best for the person going through menopause and should include open dialogue with their physician or health care team."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease

FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...

Long-Term Study of Postmenopausal Women Does Not Support Many Preventive Therapies

THURSDAY, May 2, 2024 -- The longitudinal Women's Health Initiative trials do not support hormone therapy for cardiovascular disease prevention, calcium and vitamin D...

Intensive HTN Treatment Cuts Early T2D Diagnosis-Linked CVD Event Risk

MONDAY, April 29, 2024 -- More intensive hypertensive therapy significantly reduces the excess risk for cardiovascular disease (CVD) events associated with earlier hypertension...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.